Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John R. Somoza is active.

Publication


Featured researches published by John R. Somoza.


Structure | 2000

Structural and kinetic analysis of Escherichia coli GDP-mannose 4,6 dehydratase provides insights into the enzyme’s catalytic mechanism and regulation by GDP-fucose

John R. Somoza; Saurabh Menon; Holly Schmidt; Diane Joseph-McCarthy; Andréa Dessen; Mark L. Stahl; William S. Somers; Francis X. Sullivan

BACKGROUND GDP-mannose 4,6 dehydratase (GMD) catalyzes the conversion of GDP-(D)-mannose to GDP-4-keto, 6-deoxy-(D)-mannose. This is the first and regulatory step in the de novo biosynthesis of GDP-(L)-fucose. Fucose forms part of a number of glycoconjugates, including the ABO blood groups and the selectin ligand sialyl Lewis X. Defects in GDP-fucose metabolism have been linked to leukocyte adhesion deficiency type II (LADII). RESULTS The structure of the GDP-mannose 4,6 dehydratase apo enzyme has been determined and refined using data to 2.3 A resolution. GMD is a homodimeric protein with each monomer composed of two domains. The larger N-terminal domain binds the NADP(H) cofactor in a classical Rossmann fold and the C-terminal domain harbors the sugar-nucleotide binding site. We have determined the GMD dissociation constants for NADP, NADPH and GDP-mannose. Each GMD monomer binds one cofactor and one substrate molecule, suggesting that both subunits are catalytically competent. GDP-fucose acts as a competitive inhibitor, suggesting that it binds to the same site as GDP-mannose, providing a mechanism for the feedback inhibition of fucose biosynthesis. CONCLUSIONS The X-ray structure of GMD reveals that it is a member of the short-chain dehydrogenase/reductase (SDR) family of proteins. We have modeled the binding of NADP and GDP-mannose to the enzyme and mutated four of the active-site residues to determine their function. The combined modeling and mutagenesis data suggests that at position 133 threonine substitutes serine as part of the serine-tyrosine-lysine catalytic triad common to the SDR family and Glu 135 functions as an active-site base.


Structure | 2003

The Structure of the Extracellular Region of Human Hepsin Reveals a Serine Protease Domain and a Novel Scavenger Receptor Cysteine-Rich (SRCR) Domain

John R. Somoza; Joseph D. Ho; Christine Luong; Manjiri Ghate; Paul A. Sprengeler; Kyle Mortara; William D. Shrader; David Sperandio; Hedy Chan; Mary E. McGrath; Bradley A. Katz

Hepsin is an integral membrane protein that may participate in cell growth and in maintaining proper cell morphology and is overexpressed in a number of primary tumors. We have determined the 1.75 A resolution structure of the extracellular component of human hepsin. This structure includes a 255-residue trypsin-like serine protease domain and a 109-residue region that forms a novel, poorly conserved, scavenger receptor cysteine-rich (SRCR) domain. The two domains are associated with each other through a single disulfide bond and an extensive network of noncovalent interactions. The structure suggests how the extracellular region of hepsin may be positioned with respect to the plasma membrane.


Journal of Molecular Biology | 2002

The Crystal Structure of Human Cathepsin F and Its Implications for the Development of Novel Immunomodulators

John R. Somoza; James T. Palmer; Joseph D. Ho

Cathepsin F is a lysosomal cysteine protease of the papain family, and likely plays a regulatory role in processing the invariant chain that is associated with the major histocompatibility complex (MHC) class II. Evidence suggests that inhibiting cathepsin F activity will block MHC class II processing in macrophages. Consequently, inhibitors of this enzyme may be useful in treating certain diseases that involve an inappropriate or excessive immune response. We have determined the 1.7A structure of the mature domain of human cathepsin F associated with an irreversible vinyl sulfone inhibitor. This structure provides a basis for understanding cathepsin Fs substrate specificity, and suggests ways of identifying potent and selective inhibitors of this enzyme.


Bioorganic & Medicinal Chemistry Letters | 2011

Quinolones as HCV NS5B polymerase inhibitors

Dange V. Kumar; Roopa Rai; Ken A. Brameld; John R. Somoza; Ravi Rajagopalan; James W. Janc; Yu M. Xia; Tony Ton; Michael B. Shaghafi; Huiyong Hu; Isabelle Lehoux; Nhat To; Wendy B. Young; Michael J. Green

Hepatitis C virus (HCV) infection is treated with a combination of peginterferon alfa-2a/b and ribavirin. To address the limitations of this therapy, numerous small molecule agents are in development, which act by directly affecting key steps in the viral life-cycle. Herein we describe our discovery of quinolone derivatives, novel small-molecules that inhibit NS5b polymerase, a key enzyme of the viral life-cycle. A crystal structure of a quinoline analog bound to NS5B reveals that this class of compounds binds to allosteric site-II (non-nucleoside inhibitor-site 2, NNI-2) of this protein.


Bioorganic & Medicinal Chemistry Letters | 2012

3-heterocyclyl quinolone inhibitors of the HCV NS5B polymerase.

Dange V. Kumar; Roopa Rai; Ken A. Brameld; Jennifer Riggs; John R. Somoza; Ravi Rajagopalan; James W. Janc; Yu M. Xia; Tony Ton; Huiyong Hu; Isabelle Lehoux; Joseph D. Ho; Wendy B. Young; Barry Hart; Michael J. Green

The discovery and optimization of a novel class of quinolone small-molecules that inhibit NS5B polymerase, a key enzyme of the HCV viral life-cycle, is described. Our research led to the replacement of a hydrolytically labile ester functionality with bio-isosteric heterocycles. An X-ray crystal structure of a key analog bound to NS5B facilitated the optimization of this series of compounds to afford increased activity against the target enzyme and in the cell-based replicon assay system.


Acta Crystallographica Section D-biological Crystallography | 2002

Expression, purification, crystallization and preliminary X-ray diffraction studies of human cathepsin F complexed with an irreversible vinyl sulfone inhibitor

Joseph D. Ho; Yana Meltser; Joseph J. Buggy; James T. Palmer; Kyle Elrod; Hedy Chan; Kyle Mortara; John R. Somoza

Cathepsin F is a cysteine protease believed to be involved in the antigen-presenting process of the class II major histocompatibility complex (MHC-II) in macrophages. It has been expressed, purified and crystallized. A complete data set to a resolution of 2.5 A has been collected at room temperature. The Laue group was determined to be orthorhombic, space group P2(1)2(1)2, with unit-cell parameters a = 68.9, b = 104.8, c = 68.5 A.


Structure | 2004

Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases

John R. Somoza; Robert J. Skene; Bradley A. Katz; Clifford D. Mol; Joseph D. Ho; Andy Jennings; Christine Luong; Andrew S. Arvai; Joseph J. Buggy; Ellen Chi; Jie Tang; Bi-Ching Sang; Erik Verner; Robert Wynands; Ellen M. Leahy; Douglas R. Dougan; Gyorgy Snell; Marc Navre; Mark W. Knuth; Ronald V. Swanson; Duncan E. McRee; Leslie W. Tari


Journal of Molecular Biology | 1993

Two crystal structures of a potently sweet protein. Natural monellin at 2.75 A resolution and single-chain monellin at 1.7 A resolution.

John R. Somoza; Fan Jiang; Liang Tong; Chul-Hee Kang; Joong Myung Cho; Sung-Hou Kim


Journal of Molecular Biology | 2011

Visualizing ATP-dependent RNA Translocation by the NS3 Helicase from HCV

Todd C. Appleby; Robert Anderson; Olga Fedorova; Anna Marie Pyle; Ruth Wang; Xiaohong Liu; Katherine M. Brendza; John R. Somoza


Protein Science | 1998

CRYSTAL STRUCTURE OF HUMAN CATHEPSIN S

Mary E. McGrath; James T. Palmer; Ddeter Brömme; John R. Somoza

Collaboration


Dive into the John R. Somoza's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge